Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7890597
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RO7890597 is an investigational small molecule drug candidate developed by Genentech. It has been evaluated in a Phase I clinical trial to assess its safety, tolerability, and pharmacokinetics following single and multiple ascending doses (SAD/MAD) in healthy adult volunteers. The Phase I study also investigated the effects of food, proton-pump inhibition (PPI), and CYP3A inhibition on the drug's pharmacokinetic profile, which are typical evaluations for characterizing the absorption, distribution, metabolism, and excretion (ADME) of an orally administered small molecule. The specific biological target and therapeutic indications for RO7890597 have not been publicly disclosed.
Beyond the preview
Go deeper on RO7890597.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7890597.